Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States

References

• Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;73:S14-S19
   PubMedGoogle Scholar
• Owda A, Elhwairis H, Narra S, et al. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail 2003;25:595-602
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006;70:1358-66
   PubMed Web of Science ®Google Scholar
• Tentori F, Blayney MJ, Albert J. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30
   PubMed Web of Science ®Google Scholar
• Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011 Jun;26(6):1948-55
   PubMed Web of Science ®Google Scholar
• NIH. USRDS 2010 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Disease, 2010
   Google Scholar
• Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin 2007;23:1561-9
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(suppl 3):S1-202
   Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-130
   Google Scholar
• Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-71
   PubMed Web of Science ®Google Scholar
• Aparicio M, Combe C, Lafage MH, et al. In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol. Nephron 1993;63:122-3
   Google Scholar
• Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321:274-9
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzalez EA, Gellens M, et al. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-32
   PubMed Web of Science ®Google Scholar
• Arenas MD, varez-Ude F, Gil MT, et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007;22:1639-44
   PubMed Web of Science ®Google Scholar
• Arenas MD, Alvarez-Ude F, Torregrosa V, et al. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis. J Nephrol 2007;20:453-61
   PubMed Web of Science ®Google Scholar
• Arenas MD, Alvarez-Ude F, Gil MT, et al. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006;21:1663-8
   PubMed Web of Science ®Google Scholar
• Al AZ, Gonzalez EA, Martin KJ, et al. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004;24:422-6
   Google Scholar
• Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44(5 Suppl 2):34-8
   PubMed Web of Science ®Google Scholar
• Danese MD, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008 Sep;3(5):1423-9
   PubMedGoogle Scholar
• Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
   PubMed Web of Science ®Google Scholar
• Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3:1718-25
   PubMed Web of Science ®Google Scholar
• Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011;26:1327-39
   PubMed Web of Science ®Google Scholar
• Floege J, Raggi P, Block GA, et al. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2010;25:1916-23
   PubMed Web of Science ®Google Scholar
• Akizawa T, Koshikawa S. Clinical study of cinacalcet in Japan. Ther Apher Dial 2008;12(1 Suppl):S13-S15
   Google Scholar
• Akiba T, Akizawa T, Tsukamoto Y, et al. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2008;12:117-25
   PubMed Web of Science ®Google Scholar
• Meola M, Petrucci I, Barsotti G. Cinacalcet reduced glandular volume in patients with SHPT [Abstract MP409]. Presented at the XLV ERA-EDTA Congress, May 10--13 2008, Stockholm, Sweden
   Google Scholar
• Os I, Bencova V, Banos A, et al. Achievement of KDOQI targets with cinacalcet (mimpara/sensipar) according to length of time on dialyses [Abstract SP394]. Presented at the XLV ERA-EDTA Congress, May 10--13 2008, Stockholm, Sweden
   Google Scholar
• Arenas MD, Rebollo P, Alvarez-Ude F, et al. Is cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis? Nefrologia 2008;28:511-6
   Google Scholar
• Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, de Francisco AL. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New Engl J Med 2004;350:1516-25
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248-54
   PubMed Web of Science ®Google Scholar
• Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-83
   PubMed Web of Science ®Google Scholar
• Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24
   PubMed Web of Science ®Google Scholar
• Lien YHH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1232-7
   PubMed Web of Science ®Google Scholar
• Moe SM, Cunningham J, Bommer J. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCL. Nephrol Dial Transplant 2005;20:2186-93
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
   PubMed Web of Science ®Google Scholar
• Lucchi L, Stipo L, Perrone S, et al. Early initiation of cinacalcet (cn) for the treatment of secondary hyperparathyroidism (shpt) in hemodialysis patients [Abstract MP398]. Presented at the XLV ERA-EDTA Congress, May 10--13 2008, Stockholm, Sweden
   Google Scholar
• Portoles J, Tato A, Lopez-Sanchez P, et al. Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment. A one-year, prospective study. Nefrologia 2008;28:419-24
   Google Scholar
• Meier PD, Hertner H, Jungbluth M, et al. KDOQI target achievement is improved with cinacalcet in clinical practice – the Swiss OPTIMIZE survey. [Abstract P54]. Presented at the 41st Annual Meeting Swiss Society of Nephrology. Kursaal Interlaken December 2--4, 2009
   Google Scholar
• Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 2007;39:1209-16
   PubMed Web of Science ®Google Scholar
• Sterrett JR, Strom J, Stummvoll HK, et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007;68:10-17
   PubMed Web of Science ®Google Scholar
• Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007;2:898-905
   PubMed Web of Science ®Google Scholar
• Shireman TI, Almehmi A, Wetmore JB, et al. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010;56:1108-16
   Google Scholar
• Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007;11(18)
   Google Scholar
• Garside R, Pitt M, Anderson R, et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007;22:1428-36
   PubMed Web of Science ®Google Scholar
• Eandi M, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010;28):1041-54
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Hemodial Int 2007;11:62-71
   Google Scholar
• Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003;41:1267-77
   Google Scholar
• Trespalacios FC, Taylor AJ, Agodoa LY, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 2002;62:1799-805
   Google Scholar
• Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004;66:2010-6
   PubMed Web of Science ®Google Scholar
• Gastanaga V, Zhao S, Stuccio-White N, et al. Incidence rates of hospitalization-associated bone fractures in dialysis patients in the United States Renal Data System. Presented at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 24--27, 2006. Lisbon, Portugal
   Google Scholar
• Li S, Chen Y-W, Peng Y, et al. Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis. 2011 Apr; 57(4):602-11
   Google Scholar
• US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases, 2009
   Google Scholar
• US Department of Health and Human Services. Centers for Medicare and Medicaid Services. Healthcare Common Procedure Coding System. Medicare Part B Drugs Average Price (ASP). 2009. http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/ [Last accessed May 20 2010]
   Google Scholar
• 2009 Drug Topics Red Book. Montvale, NJ: Medical Economics, 2009
   Google Scholar
• Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin 2007;23:1561-9
   PubMed Web of Science ®Google Scholar
• Duh Q-Y. Current investigation for primary hyperparathyroidism. Hyperparathyroidism 8th Postgraduate Course in Endocrine Surgery, September 22, 2006, Capsis Beach, Crete
   Google Scholar
• HCUPnet. Healthcare Cost and Utilization Project (HCUP). 1993-2008. Rockville, MD: Agency for Healthcare Research and Quality. http://hcupnet.ahrq.gov/. Accessed May 5, 2010
   Google Scholar
• US Department of Labor. Bureau of Labor Statistics. http://www.bls.gov/cpi/home.htm#overview. Accessed February 23, 2009
   Google Scholar
• de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32
   PubMed Web of Science ®Google Scholar
• Taylor DC, Pandya A, Thompson D, et al. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. Eur J Health Econ 2009;10:255-65
   PubMed Web of Science ®Google Scholar
• Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002 Oct;13:(10):768-76
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-9
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239-45
   PubMed Web of Science ®Google Scholar
• Cases A, Vera M, Lopez Gomez JM. [Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy]. Nefrologia 2002;22(1 Suppl):68-74
   Google Scholar
• Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-35
   PubMed Web of Science ®Google Scholar
• Marco MP, Craver L, Betriu A. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int 2003;63:S111-4
   Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87
   PubMed Web of Science ®Google Scholar
• Spiegel DM, Raggi P, Mehta R, et al. Coronary and aortic calcifications in patients new to dialysis. Hemodial Int 2004;8:265-72
   PubMedGoogle Scholar
• Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010 Sep;78(6):578-89
   Google Scholar
• Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;22:417-30
   PubMed Web of Science ®Google Scholar
• Iannazzo S, Pradelli L, Chiroli S. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism (SHPT) in five European countries. Presented at the International Society for Pharmacoeconomics and Outcomes Research 13th Annual European Congress, Toronto, ON, Canada, May 3--7, 2008
   Google Scholar
• Amgen. Advisory board to explore the relationship between vascular calcification and clinical and health outcomes in dialysis patients. Amgen data on file. 2010
   Google Scholar
• Stevenson M, Lyold Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 Jun;9(22):1-160
   Google Scholar
• Kim J, Dylan M, Doan Q, et al. Association of elevated serum parathyroid hormone (PTH) and calcium with hip, vertebral, or pelvic fracture in hemodialysis patients [Abstract S026]. Presented at: ERA-EDTA Congress, 15--18 May 2004, Lisbon, Portugal
   Google Scholar